+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Source (Bone Marrow, Mesenchymal Stem Cells), By Application (Cancer, Neurodegenerative Disorders), By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2022
  • Region: Global
  • Grand View Research
  • ID: 5712518
Description Jump to:
The global autologous cell therapy market size is expected to reach USD 24.31 billion by 2030. The market is expected to expand at a CAGR of 19.4% from 2022 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights

  • Based on sources, the bone marrow segment held the majority of the market share of around 42% in 2021 attributed to its benefits over a donor’s stem cells to treat different diseases as these cells are taken from the patient itself
  • Based on application, the cancer segment dominated the market in terms of revenue share in 2021 and is also expected to witness the fastest growth at a CAGR of 20.7%. Autologous cell therapy has proven beneficial for better management of cancer. For instance, Catalent Company mentioned the first two CAR-Ts joined in 2020 by a third autologous cell therapy Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma treatment
  • Based on end use, the hospitals & clinics segment accounted for the largest market share of around 45% in 2021 owing to increasing patient inflow in hospitals for treatments of diseases. The TCT program (Transplantation and Cellular Therapy) at the Ottawa Hospital was the first program outside the U.S. This program has received accreditation from the Foundation for the accreditation of cellular therapy (FACT)
  • In 2021, North America dominated the market in terms of revenue with a share of around 41% due to the factors such as potential advantages of autologous cell therapy over conventional therapies, rising government support, meeting regulatory requirements for manufacturing, growing burden of cancer cases has uplifted the market


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Report Scope and Objectives
1.1 Market Segmentation & Scope
1.2 Regional Scope
1.2.1 Estimates And Forecast Timeline
1.3 Objectives
1.3.1 Objective - 1
1.3.2 Objective - 2
1.3.3 Objective - 3
Chapter 2 Methodology
2.1 Research Methodology
2.2 Information Procurement
2.2.1 Purchased Database
2.2.2 Internal Database
2.2.3 Secondary Sources
2.2.4 Primary Research
2.3 Information Or Data Analysis
2.3.1 Data Analysis Models
2.4 Market Formulation & Validation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.5.2 Volume Price Analysis (Model 2)
2.6 List Of Secondary Sources
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Source
3.2.2 Application
3.2.3 End Use
3.2.4 Region
3.3 Competitive Insights
3.4 Autologous Cell Therapy Market Outlook, 2021
Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Ancillary Market Outlook
4.2 Autologous Cell Therapy Market Dynamics
4.2.1 Market Driver Analysis
4.2.2 Market Restraint Analysis
4.3 Autologous Cell Therapy Market: Business Environment Analysis Tools
4.3.1 Porter’s Five Forces Analysis
4.3.1.1 Threat of new entrants
4.3.1.2 Bargaining power of suppliers
4.3.1.3 Bargaining power of buyers
4.3.1.4 Competitive rivalry
4.3.1.5 Threat of substitutes
4.3.2 Pestel Analysis
4.3.2.1 Political & Legal Landscape
4.3.2.2 Economic Landscape
4.3.2.3 Technological Landscape
4.4 Penetration & Growth Prospect Mapping
4.5 Impact Of Covid-19 On Autologous Cell Therapy Market
Chapter 5 Autologous Cell Therapy Market: Source Analysis
5.1 Autologous Cell Therapy Market Share Analysis, 2021 & 2030
5.2 Autologous Cell Therapy Market: Segment Dashboard:
5.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The Services Segment
5.3.1 Bone Marrow
5.3.1.1 Bone Marrow Market, 2017 - 2030 (USD Million)
5.3.2 Epidermis
5.3.2.1 Epidermis Market, 2017 - 2030 (USD Million)
5.3.3 Mesenchymal Stem Cells
5.3.3.1 Mesenchymal Stem Cells Market, 2017 - 2030 (USD Million)
5.3.4 Haematopoietic Stem Cells
5.3.4.1 Haematopoietic Stem Cells Market, 2017 - 2030 (USD Million)
5.3.5 Chondrocytes
5.3.5.1 Chondrocytes Market, 2017 - 2030 (USD Million)
5.3.6 Others
5.3.6.1 Others Market, 2017 - 2030 (USD Million)
Chapter 6 Autologous Cell Therapy Market: Application Analysis
6.1 Autologous Cell Therapy Application Market Share Analysis, 2021 & 2030
6.2 Autologous Cell Therapy Application Market: Segment Dashboard:
6.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The Application Segment
6.3.1 Cancer
6.3.1.1 Cancer Market, 2017 - 2030 (USD Million)
6.3.2 Neurodegenerative Disorders
6.3.2.1 Neurodegenerative Disorders Market, 2017 - 2030 (USD Million)
6.3.3 Cardiovascular Disorders
6.3.3.1 Cardiovascular Disorders Market, 2017 - 2030 (USD Million)
6.3.4 Autoimmune Disorders
6.3.4.1 Autoimmune Disorders Market, 2017 - 2030 (USD Million)
6.3.5 Orthopedics
6.3.5.1 Orthopedics Market, 2017 - 2030 (USD Million)
6.3.6 Wound Healing
6.3.6.1 Wound Healing Market, 2017 - 2030 (USD Million)
6.3.7 Others
6.3.7.1 Others Market, 2017 - 2030 (USD Million)
Chapter 7 Autologous Cell Therapy Market: End-Use Analysis
7.1 Autologous Cell Therapy End-Use Market Share Analysis, 2021 & 2030
7.2 Autologous Cell Therapy End-Use Market: Segment Dashboard:
7.3 Market Size & Forecasts And Trend Analyses, 2017 To 2030 For The End-Use Segment
7.3.1 Hospitals & Clinics
7.3.1.1 Hospitals & Clinics Market, 2017 - 2030 (USD Million)
7.3.2 Ambulatory Centers
7.3.2.1 Ambulatory Centers Market, 2017 - 2030 (USD Million)
7.3.3 Academics & Research
7.3.3.1 Academics & Research Market, 2017 - 2030 (USD Million)
7.3.4 Others
7.3.4.1 Others Market, 2017 - 2030 (USD Million)
Chapter 8 Autologous Cell Therapy Market: Regional Analysis
8.1 Autologous Cell Therapy Regional Market Share Analysis, 2021 & 2030
8.2 Regional Market Snapshot
8.3 North America
8.3.1 North America Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.3.3 Canada
8.3.3.1 Canada Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4 Europe
8.4.1 Europe Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.2 U.K.
8.4.2.1 U.K. Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.3 Germany
8.4.3.1 Germany Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.4 France
8.4.4.1 France Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.5 Italy
8.4.5.1 Italy Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.6 Spain
8.4.6.1 Spain Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.4.7 Russia
8.4.7.1 Russia Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.2 Japan
8.5.2.1 Japan Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.3 China
8.5.3.1 China Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.4 India
8.5.4.1 India Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.5 Australia
8.5.5.1 Australia Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.6 South Korea
8.5.6.1 South Korea Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.5.7 Singapore
8.5.7.1 Singapore Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.6 Latin America
8.6.1 Latin America Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.6.3 Mexico
8.6.3.1 Mexico Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.6.4 Argentina
8.6.4.1 Argentina Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.6.5 Colombia
8.6.5.1 Colombia Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.7 Middle East And Africa (MEA)
8.7.1 MEA Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.7.3 Saudi Arabia
8.7.3.1 Saudi Arabia Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
8.7.4 UAE
8.7.4.1 UAE Autologous Cell Therapy Market, 2017 - 2030 (USD Million)
Chapter 9 Competitive Analysis
9.1 Recent Developments & Impact Analysis, By Key Market Participants
9.2 Company Profiles
9.2.1 BRAINSTORM CELL THERAPEUTICS INC.
9.2.1.1 Company overview
9.2.1.2 Product benchmarking
9.2.1.3 Strategic initiatives
9.2.2 HOLOSTEM TERAPIE AVANZATE S.R.L
9.2.2.1 Company overview
9.2.2.2 Product benchmarking
9.2.2.3 Strategic initiatives
9.2.3 PHARMICELL CO. INC
9.2.3.1 Company overview
9.2.3.2 Product benchmarking
9.2.4 OPEXA THERAPEUTICS
9.2.4.1 Company overview
9.2.4.2 Product benchmarking
9.2.5 LISATA THERAPEUTIC (CALADRIUS BIOSCIENCES INC)
9.2.5.1 Company overview
9.2.5.2 Product benchmarking
9.2.6 U.S. STEM CELL INC
9.2.6.1 Company overview
9.2.6.2 Product benchmarking
9.2.7 LONZA
9.2.7.1 Company overview
9.2.7.2 Product benchmarking
9.2.7.3 Strategic initiatives
9.2.8 BRISTOL MYERS SQUIBB
9.2.8.1 Company overview
9.2.8.2 Product benchmarking
9.2.8.3 Strategic initiatives
9.2.9 NOVARTIS
9.2.9.1 Company overview
9.2.9.2 Product benchmarking
9.2.9.3 Strategic initiatives
9.2.10 AUTOLUS THERAPEUTICS
9.2.10.1 Company overview
9.2.10.2 Product benchmarking
9.2.10.3 Strategic initiatives
9.2.11 TEGO SCIENCE
9.2.11.1 Company overview
9.2.11.2 Product benchmarking
9.2.11.3 Strategic initiatives
9.2.12 CORNING INCORPORATED
9.2.12.1 Company overview
9.2.12.2 Product benchmarking
9.2.13 BIO ELPIDA
9.2.13.1 Company overview
9.2.13.2 Product benchmarking
9.2.14 VERICEL CORPORATION
9.2.14.1 Company overview
9.2.14.2 Product benchmarking
9.2.15 CATALENT, INC
9.2.15.1 Company overview
9.2.15.2 Product benchmarking
9.2.15.3 Strategic initiatives
9.2.16 SARTORIUS AG
9.2.16.1 Company overview
9.2.16.2 Product benchmarking
9.2.16.3 Strategic initiatives
List of Tables
Table 1 List of secondary sources
TABLE 2 North America autologous cell therapy estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 3 North America autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 4 North America autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 5 North America autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 6 U.S. autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 7 U.S. autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 8 U.S. autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 9 Canada autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 10 Canada autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 11 Canada autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 12 Europe autologous cell therapy estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 13 Europe autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 14 Europe autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 15 Europe autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 16 U.K. autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 17 U.K. autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 18 U.K. autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 19 Germany autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 20 Germany autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 21 Germany autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 22 France autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 23 France autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 24 France autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 25 Italy autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 26 Italy Autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 27 Italy autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 28 Spain autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 29 Spain autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 30 Spain autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 31 Russia autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 32 Russia autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 33 Russia autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 34 Asia Pacific autologous cell therapy estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 35 Asia Pacific autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 36 Asia Pacific autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 37 Asia Pacific autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 38 Japan autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 39 Japan autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 40 Japan autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 41 China autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 42 China autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 43 China autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 44 India autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 45 India autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 46 India autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 47 Australia autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 48 Australia autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 49 Australia autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 50 South Korea autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 51 South Korea autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 52 South Korea autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 53 Singapore autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 54 Singapore autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 55 Singapore autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 56 Latin America autologous cell therapy estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 57 Latin America autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 58 Latin America autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 59 Latin America autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 60 Brazil autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 61 Brazil autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 62 Brazil autologous cell therapy estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
TABLE 63 Mexico autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 64 Mexico autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 65 Mexico autologous cell therapy estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
TABLE 66 Argentina autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 67 Argentina autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 68 Argentina autologous cell therapy estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
TABLE 69 MEA autologous cell therapy estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 70 MEA autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 71 MEA autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 72 MEA autologous cell therapy estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
TABLE 73 South Africa autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 74 South Africa autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 75 South Africa autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 76 Saudi Arabia autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 77 Saudi Arabia autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 78 Saudi Arabia autologous cell therapy estimates and forecasts, by end use, 2017 - 2030 (USD Million)
TABLE 79 UAE autologous cell therapy estimates and forecasts, by source, 2017 - 2030 (USD Million)
TABLE 80 UAE autologous cell therapy estimates and forecasts, by application, 2017 - 2030 (USD Million)
TABLE 81 UAE autologous cell therapy estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
List of Figures
FIG. 1 Autologous cell therapy market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value chain based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Autologous cell therapy market outlook, 2021 (USD Million)
FIG. 10 Market trends & outlook
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 Autologous cell therapy market share analysis, 2021 & 2030 (USD Million)
FIG. 15 Autologous cell therapy market: Segment dashboard
FIG. 16 Bone marrow market, 2017 - 2030 (USD Million)
FIG. 17 Epidermis market, 2017 - 2030 (USD Million)
FIG. 18 Mesenchymal stem cells market, 2017 - 2030 (USD Million)
FIG. 19 Haematopoietic stem cells market, 2017 - 2030 (USD Million)
FIG. 20 Chondrocytes market, 2017 - 2030 (USD Million)
FIG. 21 Others market, 2017 - 2030 (USD Million)
FIG. 22 Autologous cell therapy application market share analysis, 2021 & 2030 (USD Million)
FIG. 23 Autologous cell therapy application market: Segment dashboard
FIG. 24 Cancer market, 2017 - 2030 (USD Million)
FIG. 25 Neurodegenerative disorders market, 2017 - 2030 (USD Million)
FIG. 26 Cardiovascular disorders market, 2017 - 2030 (USD Million)
FIG. 27 Autoimmune disorders market, 2017 - 2030 (USD Million)
FIG. 28 Orthopedics market, 2017 - 2030 (USD Million)
FIG. 29 Wound healing market, 2017 - 2030 (USD Million)
FIG. 30 Others market, 2017 - 2030 (USD Million)
FIG. 31 Autologous cell therapy end use market share analysis, 2021 & 2030 (USD Million)
FIG. 32 Autologous cell therapy end use market: Segment dashboard
FIG. 33 Hospitals & clinics market, 2017 - 2030 (USD Million)
FIG. 34 Ambulatory centers market, 2017 - 2030 (USD Million)
FIG. 35 Academics & research market, 2017 - 2030 (USD Million)
FIG. 36 Academics & research market, 2017 - 2030 (USD Million)
FIG. 37 Autologous cell therapy regional market share analysis, 2021 & 2030 (USD Million)
FIG. 38 Regional market place: Key takeaways
FIG. 39 North America autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 40 U.S. autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 41 Canada autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 42 Europe autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 43 U.K. autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 44 Germany autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 45 France autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 46 Italy autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 47 Spain autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 48 Russia autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 49 Asia Pacific autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 50 Japan autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 51 China autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 52 India autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 46 Australia autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 47 South Korea autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 48 Singapore autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 53 Latin America autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 54 Brazil autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 55 Mexico autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 56 Argentina autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 57 Colombia autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 58 MEA autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 59 South Africa autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 60 Saudi Arabia autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 61 UAE autologous cell therapy market, 2017 - 2030 (USD Million)
FIG. 62 Strategy framework

Companies Mentioned

  • BRAINSTORM CELL THERAPEUTICS INC.
  • HOLOSTEM TERAPIE AVANZATE S.R.L
  • PHARMICELL CO. INC
  • OPEXA THERAPEUTICS
  • LISATA THERAPEUTIC (CALADRIUS BIOSCIENCES INC)
  • U.S. STEM CELL INC
  • LONZA
  • BRISTOL MYERS SQUIBB
  • NOVARTIS
  • AUTOLUS THERAPEUTICS
  • TEGO SCIENCE
  • CORNING INCORPORATED
  • BIO ELPIDA
  • VERICEL CORPORATION
  • CATALENT, INC
  • SARTORIUS AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2022
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 5.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 24.31 Billion
Compound Annual Growth Rate19.4%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Global Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Cell Therapy Market Size, Share & Trends Analysis Report by Therapy Type (Autologous (Stem Cell Therapies, Non-stem Cell Therapies), Allogeneic), Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • Report
  • 110 Pages
  • Global
From
Global Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Forecast 2024-2030 - Product Image

Global Cell & Gene Therapy Manufacturing Services Market by Type (Cell Therapy, Gene Therapy), Indication (Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases), Application, End-User - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
Global Autologous Cell Therapy Market Report and Forecast 2024-2032 - Product Image

Global Autologous Cell Therapy Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
Cell Therapy - Global Strategic Business Report - Product Image

Cell Therapy - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Autologous Cell Therapy Global Market Report 2024 - Product Image

Autologous Cell Therapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.